Taraxerol |
| رقم الكتالوجGC60352 |
Taraxerol معزول عن Abroma augusta L ، وله تأثيرات مضادة للالتهابات ومضادة للسرطان
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 127-22-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Taraxerol has anti-inflammatory and anticancer effects. Taraxerol attenuates acute inflammation by inhibiting NF-κB signaling[5,6].
Taraxerol downregulates the expression of proinflammatory mediators in macrophages by interfering with the activation of TAK1 and Akt, thus preventing NF-κB activation[3].
Taraxerol enhanced ROS levels and attenuated the MMP (Δψm) in HeLa cells. Taraxerol induced apoptosis mainly via the mitochondrial pathway including the release of cytochrome c to the cytosol and activation of caspases 9 and 3, and anti-poly (ADPribose) polymerase (PARP). Taraxerol could induce the down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax. It suppressed the PI3K/ Akt signaling pathway [1].
Taraxerol treatment significantly attenuated carrageenan induced paw edema 2 h onward. The anti-inflammatory effect of taraxerol was sustained up to 4 h[2]. Taraxerol (20mg/kg, p.o.) treatment stimulated glucose metabolism in skeletal muscle, regulated blood glycaemic status and lipid profile in the sera, reduced the secretion of pro-inflammatory cytokines, and restored the renal physiology in T2D rats[4]. AChE activity inhibition in animals and indicate that Taraxerol has anti-amnesic activity that may hold significant therapeutic value in alleviating certain memory impairments observed in AD[7].
References:
[1]: Yaoi X, Lu B, et,al. Taraxerol Induces Cell Apoptosis through A Mitochondria-Mediated Pathway in HeLa Cells. Cell J. 2017 Oct;19(3):512-519. doi: 10.22074/cellj.2017.4543. Epub 2017 Aug 19. PMID: 28836414; PMCID: PMC5572297.
[2]: Khanra R, Dewanjee S, et,al. Taraxerol, a pentacyclic triterpene from Abroma augusta leaf, attenuates acute inflammation via inhibition of NF-κB signaling. Biomed Pharmacother. 2017 Apr;88:918-923. doi: 10.1016/j.biopha.2017.01.132. Epub 2017 Feb 6. PMID: 28178622.
[3]: Yao X, Li G, et,al. Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation. Int Immunopharmacol. 2013 Feb;15(2):316-24. doi: 10.1016/j.intimp.2012.12.032. Epub 2013 Jan 15. PMID: 23333629.
[4]: Khanra R, Bhattacharjee N, et,al. Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats. Biomed Pharmacother. 2017 Oct;94:726-741. doi: 10.1016/j.biopha.2017.07.112. Epub 2017 Aug 9. PMID: 28802226.
[5]: Khanra R, Dewanjee S, et,al. (Malvaceae) leaf extract attenuates diabetes induced nephropathy and cardiomyopathy via inhibition of oxidative stress and inflammatory response. J Transl Med. 2015 Jan 16;13:6. doi: 10.1186/s12967-014-0364-1. PMID: 25591455; PMCID: PMC4301895.
[6]: Tsao CC, Shen YC, et,al. New diterpenoids and the bioactivity of Erythrophleum fordii. Bioorg Med Chem. 2008 Nov 15;16(22):9867-70. doi: 10.1016/j.bmc.2008.09.021. Epub 2008 Sep 12. PMID: 18926710.
[7]: BertÉ TE, Dalmagro AP, Zimath PL, GonÇalves AE, Meyre-Silva C, BÜrger C, Weber CJ, Dos Santos DA, Cechinel-Filho V, de Souza MM. Taraxerol as a possible therapeutic agent on memory impairments and Alzheimer's disease: Effects against scopolamine and streptozotocin-induced cognitive dysfunctions. Steroids. 2018 Apr;132:5-11. doi: 10.1016/j.steroids.2018.01.002. PMID: 29355563.
| Cell experiment [1]: | |
|
Cell lines |
RAW264.7 macrophages |
|
Preparation Method |
The cells were treated with various concentrations of taraxerol or LPS plus taraxerol for 24 h. Then cells were incubated with 5 mg/ml of MTT working solution for 4 h at 37°C. After being treated with 100 µl of DMSO to dissolve the crystals, the cells were detected under an ELx800 Universal Microplate Reader to measure the absorbance at 570 nm. |
|
Reaction Conditions |
0、10、20、40 μM Taraxerol for 1h |
|
Applications |
Taraxerol downregulates the expression of proinflammatory mediators in macrophages by interfering with the activation of TAK1 and Akt, thus preventing NF-κB activation. |
| Animal experiment [2]: | |
|
Animal models |
Wistar rats (♂, 150 ± 20 g) |
|
Preparation Method |
groups were treated with taraxerol at the doses of 5 and 10 mg/kg, i.p., respectively. |
|
Dosage form |
5 and 10 mg/kg Taraxerol for 0-4h |
|
Applications |
Taraxerol treatment significantly attenuated carrageenan induced paw edema 2 h onward. The anti-inflammatory effect of taraxerol was sustained up to 4 h. |
|
References: [1]. Yao X, Li G, et,al. Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation. Int Immunopharmacol. 2013 Feb;15(2):316-24. doi: 10.1016/j.intimp.2012.12.032. Epub 2013 Jan 15. PMID: 23333629. |
|
| Cas No. | 127-22-0 | SDF | |
| Canonical SMILES | C[C@]12C3=CC[C@@](C)(CCC(C)(C)C4)[C@]4([H])[C@@]3(CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O)CC5)C)([H])CC2)C)C | ||
| Formula | C30H50O | M.Wt | 426.72 |
| الذوبان | Soluble in Chloroform | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL |
| 5 mM | 468.7 μL | 2.3435 mL | 4.6869 mL |
| 10 mM | 234.3 μL | 1.1717 mL | 2.3435 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *